Table 2.
Antibacterial study of dextran sulfate sodium (DSS) nanoparticles of batch 3.
| Organisms | Concentration (CFUa/mL) | MIC (µg/mL) | Zone of inhibition (mm) | |
|---|---|---|---|---|
| DSS nanoparticles | Ciprofloxacin (50 µg/mL) | |||
| Bacillus subtilis | 2 × 10−5 | 150 | 23.5 ± 2 | 25.5 ± 1.2 |
| Staphylococcus aureus | 4 × 10−5 | 200 | 20.8 ± 1 | 25 ± 0.8*** |
| Streptococcus pyogenes | 4 × 10−3 | 250 | 24.6 ± 0.8 | 25.6 ± 0.9 |
| Escherichia coli | 3 × 10−5 | 150 | 26 ± 1.2 | 27 ± 1.6 |
| Pseudomonas aeruginosa | 2 × 10−3 | 200 | 21.8 ± 1 | 22.8 ± 1 |
| Klebsiella pneumoniae | 2 × 10−4 | 250 | 22 ± 2 | 24.16 ± 1.3 |
| Proteus vulgaris | 3 × 10−3 | 250 | 20.5 ± 0.9 | 22.16 ± 1.3* |
Each value is the mean of 6 batches with standard deviation.
The statistical analyses were done using the Prism 9, Graph Pad Instat software system, USA.
The test values were compared with the standard drug values using Dunnet’s post hoc test.
***Extremely significant at p ≤ 0.001when compared to DSS nanoparticles; *significant at p ≤ 0.01 when compared to DSS nanoparticles.
aCFU colony forming unit.